Premium
Comparison of gadopentetate dimeglumine and albumin‐(Gd‐DTPA) 30 for microvessel characterization in an intracranial glioma model
Author(s) -
Ostrowitzki Susanne,
Fick James,
Roberts Timothy P. L.,
Wendland Michael F.,
Aldape Kenneth D.,
Mann Jeffry S.,
Israel Mark A.,
Brasch Robert C.
Publication year - 1998
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880080408
Subject(s) - microvessel , gadolinium dtpa , glioma , medicine , albumin , gadolinium , nuclear medicine , glioblastoma , magnetic resonance imaging , radiology , pathology , chemistry , immunohistochemistry , cancer research , organic chemistry
To compare the performance of macromolecular albumin gadolinium‐diethylenetriamine pentaacetic acid (Gd‐DTPA) 30 and low molecular weight gadopentetate dimeglumine for microvessel characterization, we examined an intracranial 9L glioma model in which increased angiogenesis, hypervascularity, and hyperpermeability mimic characteristics of clinical malignant brain tumors. Dynamic MRI data were analyzed using a bidirectional, two‐compartment kinetic model to extract quantitative estimates for fractional blood volume (fBV) and permeability surface area product (PS). Three criteria were used for comparison of contrast agent performance: ( a ) tumor conspicuity, defined as the contrast‐to‐noise ratio (CNR); ( b ) dynamic range of differential permeability estimates between tumor and normal brain; ( c ) reasonableness of blood volume estimates. Gadopentetate was superior to macromolecular albumin‐(Gd‐DTPA) 30 for detection of 9L brain gliomas and for measurements of hyperpermeability.